Cortisol, Depression, and the HPA Axis: What CBG Research Suggests

Depression is not a single condition with a single cause. It is a clinical syndrome with multiple subtypes, multiple pathophysiological pathways, and substantial biological heterogeneity between individuals who receive the same diagnosis. Any article claiming to explain the connection between a specific compound and depression as a whole should be treated with immediate scepticism. This article does not make that claim. It examines one specific, well-established biological pathway — the HPA axis dysregulation pathway — and asks where CBG's documented mechanisms are relevant to that pathway, with appropriate honesty about what that relevance does and does not mean.

The HPA Axis Dysregulation Pathway in Depression

The most consistently replicated biological finding in major depression is HPA axis dysregulation. Elevated cortisol, impaired cortisol feedback suppression, and blunted diurnal cortisol variation are found in a significant proportion — though not all — of people with major depressive disorder. This is Tier 1 biology: it is established in clinical research spanning decades and across multiple study designs.

The causal direction is not simple. Chronic stress with sustained HPA activation can precede and contribute to depressive episodes — the stress-sensitisation model of depression. But depression itself also drives HPA dysregulation, creating a bidirectional relationship. The biological mechanisms through which sustained cortisol elevation contributes to depressive symptomology are multiple and include hippocampal neuroplasticity reduction, suppression of neurogenesis in the dentate gyrus, downregulation of BDNF (brain-derived neurotrophic factor), and alteration of the serotonergic and dopaminergic systems whose dysfunction is central to the phenomenology of depression.

Hippocampal volume reduction — documented in MRI studies of people with major depression, particularly those with chronic or recurrent episodes — is attributed in part to cortisol's suppression of hippocampal neuroplasticity. The hippocampus expresses glucocorticoid receptors at high density and is among the most vulnerable brain regions to sustained cortisol elevation. Hippocampal BDNF reduction under chronic cortisol exposure is one of the more specific and replicated mechanisms in this pathway.

The ECS in HPA-Depression Biology

The endocannabinoid system sits within the HPA axis at several points that are directly relevant to the cortisol-depression pathway. CB1 receptors in the hippocampus, amygdala, and prefrontal cortex modulate the limbic stress response that drives HPA activation. Anandamide signalling at hippocampal CB1 receptors has been shown in preclinical models to promote hippocampal neuroplasticity and BDNF expression — the same neurotrophic factor that cortisol suppresses. ECS tone in limbic circuits is part of the mechanism through which the HPA axis terminates the stress response after acute stressors.

Under chronic stress conditions, the endocannabinoid system becomes impaired — CB1 receptor downregulation, reduced anandamide availability, and diminished ECS-mediated HPA termination create a situation in which cortisol stays elevated longer and the hippocampal neuroplasticity consequences accumulate. There is preclinical evidence that restoring ECS tone in these circuits — through FAAH inhibition increasing anandamide, or through direct CB1 activation — can produce antidepressant-like effects in rodent models of chronic stress-induced depression.

Where CBG's Mechanisms Are Relevant

CBG's documented HPA axis mechanisms — the alpha-2 adrenoceptor agonism reducing noradrenaline release, the partial CB1 agonism in limbic circuits, and the cortisol-modulating effects demonstrated in the Cuttler (2024) human trial — operate at the upstream end of the HPA-depression pathway. If CBG reduces the cortisol burden on the hippocampus by improving HPA termination, the downstream consequences for hippocampal neuroplasticity would be expected to follow from that reduction, through the same mechanisms discussed above.

This is a mechanistically coherent chain of reasoning. It is also a chain with multiple inferential links, each of which requires its own empirical support. The Cuttler trial showed cortisol reduction as an exploratory finding — not a powered primary endpoint. The connection between that cortisol reduction and hippocampal BDNF or neuroplasticity outcomes has not been examined in any CBG study. The connection between CBG use and depression outcomes in human populations has not been studied at all.

The tier structure is therefore: the HPA-depression pathway is Tier 1. CBG's HPA mechanisms are Tier 2. The inferential chain connecting CBG through those mechanisms to depression is Tier 2/3 — plausible, grounded, and worth investigating, but not established.